AGP Executive Report
Last update: 7 hours agoLegionella in Linz: Confirmed infections in the greater Linz area rose to 31 with three deaths, as investigators found another positive cooling-system sample in Leonding and continue disinfecting and sampling across homes and workplaces. Cancer care in Austria: A Vienna-led analysis reports patient-reported quality-of-life for belzutifan plus lenvatinib in post–PD-(L)1 renal cell carcinoma is comparable to cabozantinib, with no added HRQoL burden. Pain treatment update: German/Austrian-approved Exilby (cannabis-derived, non-opioid pain therapy) is moving through regulatory review and has received FDA Breakthrough Therapy status for chronic low back pain. Flu vaccine pipeline: Vivaldi Biosciences (with operations in Vienna) is advancing its DeltaFLU nasal spray influenza vaccine candidate toward 2027 trials, supported by Horizon Europe. Food safety alert: UK salmonella cases linked to imported eggs are nearing 500, and Austria is among countries reporting cases as investigators track multiple genetic clusters. Care support for residents: Lower Austria’s €1,000 Pflege- und Betreuungsscheck care grant for 2026 is open, with eligibility rules covering several foreign resident statuses. Health system pressure: A new European study estimates Parkinson’s societal cost at €22.8bn in 2019, highlighting rising demand on medical and social care.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
